http://www.pharmexec.com/pharmexec/News+Analysis/Article/list/43753 The latest business, scientific & regulatory news from the pharmaceutical and biotechnology industries. 2013-05-20T06:18:21Z http://www.pharmexec.com/pharmexec/Europe+News/FDA-Extends-Deadline-for-Avastin-Review/ArticleStandard/Article/detail/687899?contextCategoryId=43753&ref=25 September 21, 2010. 2010-09-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/392010/687899null HTML http://www.pharmexec.com/pharmexec/Europe+News/Roche-Plans-Business-Makeover/ArticleStandard/Article/detail/686186?contextCategoryId=43753&ref=25 September 08, 2010. 2010-09-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372010/686186null HTML http://www.pharmexec.com/pharmexec/Regulatory/Actos-Deemed-as-Safe-as-Avandia/ArticleStandard/Article/detail/684476?contextCategoryId=43753&ref=25 Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign? 2010-08-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352010/684476null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Lilly-Kills-Two-Alzheimers-Trials/ArticleStandard/Article/detail/683730?contextCategoryId=43753&ref=25 In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse. 2010-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342010/683730null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Amgen-Head-and-Neck-Cancer-Study-A-Disappointment/ArticleStandard/Article/detail/682763?contextCategoryId=43753&ref=25 Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone. 2010-08-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682763null HTML http://www.pharmexec.com/pharmexec/News+Analysis/NicOx-Shutters-HQ-After-Approval-Fail/ArticleStandard/Article/detail/681789?contextCategoryId=43753&ref=25 In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters. 2010-08-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322010/681789null HTML http://www.pharmexec.com/pharmexec/Deals/5-Years-Later-Conatus-Acquires-Idun/ArticleStandard/Article/detail/681404?contextCategoryId=43753&ref=25 Former Idun Pharma team buys back company from Pfizer. 2010-08-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322010/681404null HTML http://www.pharmexec.com/pharmexec/Europe+News/Sanofi-Fights-FDA-Approval-of-Generic-Lovenox/ArticleStandard/Article/detail/681321?contextCategoryId=43753&ref=25 August 2, 2010. 2010-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322010/681321null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Rethinks-Rep-Compensation/ArticleStandard/Article/detail/680852?contextCategoryId=43753&ref=25 Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented. 2010-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312010/680852null HTML http://www.pharmexec.com/pharmexec/R%26D/Pfizer-Suspends-More-Tanezunab-Trials/ArticleStandard/Article/detail/679740?contextCategoryId=43753&ref=25 Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications. 2010-07-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302010/679740null HTML http://www.pharmexec.com/pharmexec/News+Analysis/UK-Coalition-Government-Unveils-Radical-NHS-Plans/ArticleStandard/Article/detail/678876?contextCategoryId=43753&ref=25 July 14, 2010. 2010-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678876null HTML http://www.pharmexec.com/pharmexec/Regulatory/FDA-to-Weigh-In-on-Obesity-Drug/ArticleStandard/Article/detail/678935?contextCategoryId=43753&ref=25 Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are. 2010-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678935null HTML http://www.pharmexec.com/pharmexec/Strategy/PhRMA-Announces-Billy-Tauzins-Successor/ArticleStandard/Article/detail/678934?contextCategoryId=43753&ref=25 John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September. 2010-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678934null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Berwick-Appointed-Head-of-CMS/ArticleStandard/Article/detail/678274?contextCategoryId=43753&ref=25 With a long, hard fight looming, President Obama decided to go around Congress to install Don Berwick, founder of the Institute for Healthcare Improvement, as the top administrator of the Centers for Medicaid and Medicare Services. 2010-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282010/678274null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Mixed-Criticism-on-Avandia-Effectiveness/ArticleStandard/Article/detail/676969?contextCategoryId=43753&ref=25 GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks. 2010-06-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272010/676969null HTML http://www.pharmexec.com/pharmexec/News+Analysis/FDA-Prepares-to-Walk-the-Opiate-REMS-Line/ArticleStandard/Article/detail/676972?contextCategoryId=43753&ref=25 FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access. 2010-06-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272010/676972null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Pulls-Leukemia-Treatment/ArticleStandard/Article/detail/675777?contextCategoryId=43753&ref=25 Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs? 2010-06-23T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262010/675777null HTML http://www.pharmexec.com/pharmexec/Sales/Physicians-Not-on-the-Move/ArticleStandard/Article/detail/673536?contextCategoryId=43753&ref=25 A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey. 2010-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242010/673536null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Reveals-New-Trial-Network-for-Oncology/ArticleStandard/Article/detail/673535?contextCategoryId=43753&ref=25 Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline. 2010-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242010/673535null HTML http://www.pharmexec.com/pharmexec/Europe+News/Patent-Cliff-Pushes-Pharma-to-the-Brink/ArticleStandard/Article/detail/671187?contextCategoryId=43753&ref=25 May 24, 2010. 2010-05-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222010/671187null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-and-Merck-Bullets-Dodged/ArticleStandard/Article/detail/668828?contextCategoryId=43753&ref=25 In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results 2010-05-05T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192010/668828null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Biotech-Industry-Profits-Grow-37B/ArticleStandard/Article/detail/667300?contextCategoryId=43753&ref=25 After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth? 2010-04-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182010/667300null HTML http://www.pharmexec.com/pharmexec/Regulatory/Sunshine-Laws-Stump-Compliance-Departments/ArticleStandard/Article/detail/667301?contextCategoryId=43753&ref=25 A new Cegedim Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job. 2010-04-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182010/667301null HTML http://www.pharmexec.com/pharmexec/Europe+News/Bayer-Says-Bye-to-Arthur-Higgins/ArticleStandard/Article/detail/666350?contextCategoryId=43753&ref=25 April 22, 2010. 2010-04-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172010/666350null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Discussions-About-Drug-User-Fees/ArticleStandard/Article/detail/665248?contextCategoryId=43753&ref=25 The Prescription Drug User Fee Act will expire in 2012 and FDA is working hard to renegotiate the act before that end date. The contenders: in one corner, the pharma industry; in the other, the general public and consumers - and just about everyone has an opinion about what needs to be changed. 2010-04-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665248null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Clinical-Trial-Diversity-and-You/ArticleStandard/Article/detail/665250?contextCategoryId=43753&ref=25 Lilly's aggressive approach to shrinking the racial gap in drug trials might indicate big changes for the drugmaking process. 2010-04-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665250null HTML http://www.pharmexec.com/pharmexec/Strategy/Sanofi-Aventis-Cuts-400-Jobs/ArticleStandard/Article/detail/664380?contextCategoryId=43753&ref=25 Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales. 2010-04-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152010/664380null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Rx-Sales-Jump-51-Percent-to-300-Billion-in-2009/ArticleStandard/Article/detail/663525?contextCategoryId=43753&ref=25 IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again. 2010-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142010/663525null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Inks-15-Billion-Collaboration-Deal-with-Isis/ArticleStandard/Article/detail/663527?contextCategoryId=43753&ref=25 Glaxo and Isis formed a billion-dollar alliance to create new RNA therapies for the rare and infectious disease segment. The key ingredient in the deal is Isis' drug discovery platform. Could it be a game changer? GSK thinks so. 2010-03-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142010/663527null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-and-Pfizer-to-Discount-Pneumonia-Vaccines-for-/ArticleStandard/Article/detail/662490?contextCategoryId=43753&ref=25 Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts. 2010-03-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132010/662490null HTML http://www.pharmexec.com/pharmexec/Strategy/Emerging-Markets-to-Account-for-Half-of-Market-Gro/ArticleStandard/Article/detail/661718?contextCategoryId=43753&ref=25 A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity? 2010-03-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122010/661718null HTML http://www.pharmexec.com/pharmexec/Sales/Rx-Abandonment-Rate-Continues-to-Rise/ArticleStandard/Article/detail/661719?contextCategoryId=43753&ref=25 The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens. 2010-03-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122010/661719null HTML http://www.pharmexec.com/pharmexec/News+Analysis/FDA-Gives-Red-Light-to-Ranbaxy-for-Generic-Flomax/ArticleStandard/Article/detail/659857?contextCategoryId=43753&ref=25 The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market. 2010-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102010/659857null HTML http://www.pharmexec.com/pharmexec/Deals/Astellas-Hostile-Takeover-Turns-Even-More-Hostile/ArticleStandard/Article/detail/659855?contextCategoryId=43753&ref=25 The Japan-based company filed a lawsuit against OSI Pharmaceuticals for rejecting its tender offer, but will this strategy work? 2010-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102010/659855null HTML http://www.pharmexec.com/pharmexec/Marketing/Web-Infinity---And-Beyond/ArticleStandard/Article/detail/659860?contextCategoryId=43753&ref=25 Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg. 2010-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102010/659860null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Avandia-2-Ethical-Boogaloo/ArticleStandard/Article/detail/658599?contextCategoryId=43753&ref=25 GSK is coming under serious fire again from the FDA and Senate, who say the company resorted to scientific flimflammery to keep researchers quiet about Avandia's safety risks. 2010-02-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092010/658599null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Mergers-and-Layoffs-and-Pipelines-Oh-My/ArticleStandard/Article/detail/657590?contextCategoryId=43753&ref=25 The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts. 2010-02-17T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082010/657590null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Study-Links-Paxil-to-Breast-Cancer-Patient-Deaths/ArticleStandard/Article/detail/656474?contextCategoryId=43753&ref=25 The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer. 2010-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072010/656474null HTML http://www.pharmexec.com/pharmexec/News+Analysis/No-Real-New-Money-for-Drug-Regulation/ArticleStandard/Article/detail/656473?contextCategoryId=43753&ref=25 Added funds for FDA to come from new user fees, largely for food and tobacco regulation. 2010-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072010/656473null HTML http://www.pharmexec.com/pharmexec/Europe+News/Europe-Reveals-Generic-Dominance/ArticleStandard/Article/detail/656356?contextCategoryId=43753&ref=25 February 10, 2010. 2010-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072010/656356null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Ernst-amp-Young-Puts-the-Spotlight-on-Pharma-30/ArticleStandard/Article/detail/656475?contextCategoryId=43753&ref=25 The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing. 2010-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072010/656475null HTML http://www.pharmexec.com/pharmexec/Sales/Wyeth-Purchase-Boosts-Pfizer-Profits/ArticleStandard/Article/detail/655246?contextCategoryId=43753&ref=25 Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast. 2010-02-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062010/655246null HTML http://www.pharmexec.com/pharmexec/R%26D/Palpitations-in-the-Heart-of-US-Biotech/ArticleStandard/Article/detail/655245?contextCategoryId=43753&ref=25 California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation. 2010-02-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062010/655245null HTML http://www.pharmexec.com/pharmexec/Marketing/UCB-sponsored-PatientsLikeMe-Site-is-Live/ArticleStandard/Article/detail/653856?contextCategoryId=43753&ref=25 All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media? 2010-01-27T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052010/653856null HTML http://www.pharmexec.com/pharmexec/News+Analysis/AHF-Puts-Kibosh-on-Merck-Rep-Visits/ArticleStandard/Article/detail/653855?contextCategoryId=43753&ref=25 AIDS treatment provider says the high price of Merck's Isentress is limiting patient access. Merck says banning its reps is what limits access. While Mom and Dad are fighting, does the patient lose out? 2010-01-27T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052010/653855null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Witty-Opens-GSK-Library-for-Free-Access-to-Malaria/ArticleStandard/Article/detail/652833?contextCategoryId=43753&ref=25 GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries. 2010-01-20T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042010/652833null HTML http://www.pharmexec.com/pharmexec/Regulatory/FDA-Basics-Brings-the-Agency-Out-of-the-Closet/ArticleStandard/Article/detail/651794?contextCategoryId=43753&ref=25 The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs. 2010-01-13T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032010/651794null HTML http://www.pharmexec.com/pharmexec/Regulatory/GAO-Seeks-Price-Spike-Explanation/ArticleStandard/Article/detail/651795?contextCategoryId=43753&ref=25 At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years. 2010-01-13T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032010/651795null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Antidepressants-Might-Not-Be-A-Sure-Shot/ArticleStandard/Article/detail/650516?contextCategoryId=43753&ref=25 A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen. 2010-01-06T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022010/650516null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Novartis-Bids-Big-on-Alcon/ArticleStandard/Article/detail/650517?contextCategoryId=43753&ref=25 It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon. 2010-01-06T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022010/650517null HTML http://www.pharmexec.com/pharmexec/Europe+News/Novartis-Eyes-Full-Takeover-of-Alcon/ArticleStandard/Article/detail/650048?contextCategoryId=43753&ref=25 January 04. 2010. 2010-01-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022010/650048null HTML http://www.pharmexec.com/pharmexec/Europe+News/Corrupt-Practices-Cost-Healthcare-23-Billion/ArticleStandard/Article/detail/649111?contextCategoryId=43753&ref=25 December 18, 2009. 2009-12-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/649111null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Makes-Physician-Payments-Public/ArticleStandard/Article/detail/648745?contextCategoryId=43753&ref=25 Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny? 2009-12-16T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648745null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Gilead-and-Elan-Struggle-with-Clinical-Trials/ArticleStandard/Article/detail/648744?contextCategoryId=43753&ref=25 It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths. 2009-12-16T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648744null HTML http://www.pharmexec.com/pharmexec/Regulatory/Sanofi-Gets-a-Bad-Batch-of-H1N1-Vaccines/ArticleStandard/Article/detail/648743?contextCategoryId=43753&ref=25 Sanofi-Aventis is recalling hundreds of thousands of doses of the childrens' version of its H1N1 vaccine. Conspiracy theorists are going to have a field day. 2009-12-16T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648743null HTML http://www.pharmexec.com/pharmexec/Europe+News/Personalized-Medicine-Market-To-Grow-11-Annually/ArticleStandard/Article/detail/648493?contextCategoryId=43753&ref=25 December 15, 2009. 2009-12-15T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648493null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Feds-Team-with-Drugmakers-to-Curb-Opioid-Misuse/ArticleStandard/Article/detail/647504?contextCategoryId=43753&ref=25 Painkiller abuse has become so prevalent that FDA is working with pharma to create a strategy for handling misuse of all drugs across the entire opioid category. 2009-12-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502009/647504null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pharma-Comes-Under-Fire-for-Jump-in-Rx-Prices/ArticleStandard/Article/detail/647503?contextCategoryId=43753&ref=25 Drug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle. 2009-12-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502009/647503null HTML http://www.pharmexec.com/pharmexec/Strategy/Report-Sees-Huge-Pharma-Tax-Hike-Over-Next-Decade/ArticleStandard/Article/detail/645277?contextCategoryId=43753&ref=25 A new study of industry tax professionals conducted by PricewaterhouseCoopers predicts higher taxes for Big Pharma in the wake of the global economic downturn. What can your company do to remain competitive and discover new incentives? 2009-12-02T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/645277null HTML http://www.pharmexec.com/pharmexec/Sales/Layoffs-and-Job-Cuts-Brewing-at-Sanofi-Aventis/ArticleStandard/Article/detail/645278?contextCategoryId=43753&ref=25 With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions. 2009-12-02T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/645278null HTML http://www.pharmexec.com/pharmexec/Europe+News/European-Pharma-Finally-Becomes-a-Health-Matter/ArticleStandard/Article/detail/644843?contextCategoryId=43753&ref=25 December 01 2009-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/644843null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Congress-Ups-the-Pharma-Ante-for-Health-Reform/ArticleStandard/Article/detail/643863?contextCategoryId=43753&ref=25 House bill boosts rebates and opens the door to government price negotiations. 2009-11-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482009/643863null HTML http://www.pharmexec.com/pharmexec/Marketing/FDA-Warning-Letters-Target-Illegal-Online-Pharmaci/ArticleStandard/Article/detail/643882?contextCategoryId=43753&ref=25 Feds targeted 136 Web sites offering foreign or unapproved drugs as part of International Internet Week of Action. But does the FDA campaign ignore a larger crisis endangering consumers? 2009-11-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482009/643882null HTML http://www.pharmexec.com/pharmexec/Marketing/A-Call-for-Social-Media-Guidelines/ArticleStandard/Article/detail/642665?contextCategoryId=43753&ref=25 Nearly 70 pharma execs, new media mavens, and even Joe Q. Public packed last week's FDA social media hearings to plead for some form of guidance on how to handle Tweets, blog comments, and off label discussions online. 2009-11-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472009/642665null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Clinical-Trials-Find-Drug-Effective-In-Increasing-/ArticleStandard/Article/detail/642664?contextCategoryId=43753&ref=25 Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction. 2009-11-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472009/642664null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Quick-on-the-Draw-with-RampD-Location-Plans/ArticleStandard/Article/detail/640996?contextCategoryId=43753&ref=25 Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network. 2009-11-11T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462009/640996null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Donates-50-Million-H1N1-Doses-To-WHO/ArticleStandard/Article/detail/640997?contextCategoryId=43753&ref=25 Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world. 2009-11-11T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462009/640997null HTML http://www.pharmexec.com/pharmexec/Deals/Glaxo-Vies-for-a-Second-Act-in-HIV/ArticleStandard/Article/detail/639343?contextCategoryId=43753&ref=25 A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. 2009-11-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452009/639343null HTML http://www.pharmexec.com/pharmexec/News+Analysis/JampJ-Cuts-Staff-in-Major-Restructuring-Move/ArticleStandard/Article/detail/639344?contextCategoryId=43753&ref=25 Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce. 2009-11-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452009/639344null HTML http://www.pharmexec.com/pharmexec/Marketing/Sanofi-Warned-for-Misleading-Tent-Card/ArticleStandard/Article/detail/637273?contextCategoryId=43753&ref=25 Sure, prescription information for Sanofi-Aventis's Uroxatral appears on the back of the tent card, but how can consumer?s see it if it's mounted to a pharmacy wall? 2009-10-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442009/637273null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GAO-Accuses-FDA-of-Tardy-Trial-Data/ArticleStandard/Article/detail/637272?contextCategoryId=43753&ref=25 The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program. 2009-10-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442009/637272null HTML http://www.pharmexec.com/pharmexec/Europe+News/CROs-United/ArticleStandard/Article/detail/636759?contextCategoryId=43753&ref=25 US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs. 2009-10-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442009/636759null HTML http://www.pharmexec.com/pharmexec/Europe+News/UKs-NICE-Rejects-GSK-Breast-Cancer-Treatment/ArticleStandard/Article/detail/635531?contextCategoryId=43753&ref=25 21 October 2009-10-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/432009/635531null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Jury-Sides-with-Family-in-Paxil-Birth-Defect-Case/ArticleStandard/Article/detail/634103?contextCategoryId=43753&ref=25 GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects. 2009-10-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422009/634103null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Sandoz-and-Shire-settle-Adderall-XR-Dispute/ArticleStandard/Article/detail/634102?contextCategoryId=43753&ref=25 Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if. 2009-10-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422009/634102null HTML http://www.pharmexec.com/pharmexec/Europe+News/Economist-Award-for-Bioscience-Announced/ArticleStandard/Article/detail/633542?contextCategoryId=43753&ref=25 13 October 2009-10-13T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422009/633542null HTML http://www.pharmexec.com/pharmexec/Strategy/Global-Pharma-Market-Growth-to-Grow-4-to-6-Percent/ArticleStandard/Article/detail/632250?contextCategoryId=43753&ref=25 Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates. 2009-10-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/632250null HTML http://www.pharmexec.com/pharmexec/News+Analysis/H1N1-Vaccine-Hits-the-Market/ArticleStandard/Article/detail/632251?contextCategoryId=43753&ref=25 Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe? 2009-10-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/632251null HTML http://www.pharmexec.com/pharmexec/News+Analysis/iPharm-Execi-QampA-GSKs-Deirdre-Connelly/ArticleStandard/Article/detail/630329?contextCategoryId=43753&ref=25 Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more. 2009-09-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402009/630329null HTML http://www.pharmexec.com/pharmexec/News+Analysis/JampJ-Slims-Down-Elan-Offer-sans-Tysabri/ArticleStandard/Article/detail/626746?contextCategoryId=43753&ref=25 Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move. 2009-09-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626746null HTML http://www.pharmexec.com/pharmexec/Europe+News/IMI-Announces-Next-Topics-for-Research/ArticleStandard/Article/detail/626551?contextCategoryId=43753&ref=25 15 September 2009 2009-09-15T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626551null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Lilly-Shuffles-Staff-Cuts-Thousands-of-Jobs/ArticleStandard/Article/detail/626469?contextCategoryId=43753&ref=25 Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011. 2009-09-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626469null HTML http://www.pharmexec.com/pharmexec/Europe+News/AstraZeneca-wins-over-UK-doctors/ArticleStandard/Article/detail/625465?contextCategoryId=43753&ref=25 10 September 2009 2009-09-10T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372009/625465null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Sepracor-Faces-Shareholder-Lawsuit-in-Wake-of-26B-/ArticleStandard/Article/detail/625138?contextCategoryId=43753&ref=25 Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares. 2009-09-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372009/625138null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Roche-Shifts-Execs-in-Anticipation-of-Departures/ArticleStandard/Article/detail/625139?contextCategoryId=43753&ref=25 With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders. 2009-09-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372009/625139null HTML http://www.pharmexec.com/pharmexec/Europe+News/Algeta-amp-Bayer-in-cancer-drug-deal/ArticleStandard/Article/detail/623829?contextCategoryId=43753&ref=25 3rd September 2009 2009-09-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362009/623829null HTML http://www.pharmexec.com/pharmexec/Europe+News/Global-Cancer-Cases-to-Grow-by-30-Per-Cent/ArticleStandard/Article/detail/623601?contextCategoryId=43753&ref=25 2 September 2009 2009-09-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362009/623601null HTML http://www.pharmexec.com/pharmexec/Europe/Guiding-Your-Drug-Name-to-Approval/ArticleStandard/Article/detail/617169?contextCategoryId=43753&ref=25 06 August 2009 2009-08-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/617169null HTML http://www.pharmexec.com/pharmexec/Europe+News/Pfizer-to-develop-clinical-trial-website/ArticleStandard/Article/detail/620739?contextCategoryId=43753&ref=25 21 August 2009 2009-08-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/620739null HTML http://www.pharmexec.com/pharmexec/Europe/Obama-Advisor-to-Open-Swedish-Life-Sciences-Summit/ArticleStandard/Article/detail/619614?contextCategoryId=43753&ref=25 18 August 2009 2009-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619614null HTML http://www.pharmexec.com/pharmexec/Europe/Pfizer-settles-Nigerian-Trovan-case/ArticleStandard/Article/detail/615966?contextCategoryId=43753&ref=25 3 August 2009 2009-08-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/615966null HTML http://www.pharmexec.com/pharmexec/Europe/A-busy-time-for-Sanofi/ArticleStandard/Article/detail/615488?contextCategoryId=43753&ref=25 31 July 2009 2009-07-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615488null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Signs-120M-Deal-to-Market-DMab-Overseas/ArticleStandard/Article/detail/615227?contextCategoryId=43753&ref=25 Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved. 2009-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615227null REMOTE http://www.pharmexec.com/pharmexec/News+Analysis/NHLBI-Cans-Sildenafil-Study-After-Reports-of-Sever/ArticleStandard/Article/detail/615239?contextCategoryId=43753&ref=25 Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra. 2009-07-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615239null REMOTE http://www.pharmexec.com/pharmexec/Marketing/Pfizer-Joins-Twitter-Fray/ArticleStandard/Article/detail/615237?contextCategoryId=43753&ref=25 The drug giant, last week, started tweeting about corporate initiatives, job openings, and news. Is Pfizer just jumping on the bandwagon, or is Twitter part of the company's social media strategy? Pharm Exec talks to Pfizer to find out more. 2009-07-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615237null REMOTE http://www.pharmexec.com/pharmexec/Regulatory/New-NIH-Leader-Backs-Personalized-Medicine/ArticleStandard/Article/detail/613034?contextCategoryId=43753&ref=25 Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine. 2009-07-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/613034null REMOTE http://www.pharmexec.com/pharmexec/News+Analysis/Statins-Get-Boost-from-New-Study/ArticleStandard/Article/detail/613031?contextCategoryId=43753&ref=25 Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal. 2009-07-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/613031null REMOTE http://www.pharmexec.com/pharmexec/Europe+News/European-Approval-for-Pfizer-Wyeth-Deal/ArticleStandard/Article/detail/612293?contextCategoryId=43753&ref=25 20 July 2009 2009-07-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612293null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Sanofi-Gets-Green-Light-on-Blockbuster-Heart-Treat/ArticleStandard/Article/detail/609625?contextCategoryId=43753&ref=25 Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it. 2009-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/609625null HTML http://www.pharmexec.com/pharmexec/Europe/Servier-Singled-Out-for-New-EU-Antitrust-Investiga/ArticleStandard/Article/detail/609542?contextCategoryId=43753&ref=25 08 July 2009 2009-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/609542null HTML